Anti-SARS-CoV-2 Biotherapeutics and Chemotherapeutics: An Insight into Product Specifications and Marketing Dynamics
Chemotherapeutics and biotherapeutics agents have been explored as a potential treatment for COVID-19. This study was aimed to elucidate latest update related to biotherapeutics and chemotherapeutics against COVID-19 and its variants as well as the product specifications and marketing dynamics of it...
Saved in:
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Published: |
HH Publisher
2022
|
Subjects: | |
Online Access: | http://eprints.sunway.edu.my/3013/ https://doi.org/10.36877/pmmb.a0000323 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
my.sunway.eprints.3013 |
---|---|
record_format |
eprints |
spelling |
my.sunway.eprints.30132024-08-06T05:46:33Z http://eprints.sunway.edu.my/3013/ Anti-SARS-CoV-2 Biotherapeutics and Chemotherapeutics: An Insight into Product Specifications and Marketing Dynamics Vijay, Kotra Mallem, Dinakar Anil Kumar, Kanuri Mahesh Reddy, Burra Shaik, Nyamathullah Ying, Looi Shu Khairul Anwar, Husain Vrala, Ravi Sudhakar, Madhavedi Goh, Khang Wen Sam, Toong Hai Long, Chiau Ming * RA Public aspects of medicine RM Therapeutics. Pharmacology Chemotherapeutics and biotherapeutics agents have been explored as a potential treatment for COVID-19. This study was aimed to elucidate latest update related to biotherapeutics and chemotherapeutics against COVID-19 and its variants as well as the product specifications and marketing dynamics of its pharmacotherapies. There are several chemotherapeutics that have been studied for the treatment of COVID-19, including Paxlovid (Nirmatrelvir & Ritonavir) fixed dose combination, nirmatrelvir and ritonavir fixed dose combination, Remdesivir (Vekulary/Covifor) fixed dose combination, chloroquine and hydroxychloroquine, molnupiravir, favipiravir, Infliximab (Remsima®) fixed dose combination tocilizumab (Actimera), casirivimab+imdevimab (Ronapreve) fixed dose combination, ivermectin, methylprednisole. These drugs have been repurposed for use in COVID-19 due to their antiviral properties and ability to reduce inflammation. The COVID-19 death cases have significantly reduced because of tested efficacy of advanced biotherapeutics and chemotherapeutics. As for marketing dynamics, the demand for chemotherapeutics for the treatment of COVID-19 has increased significantly since the outbreak of the pandemic. Hence, the prices of anti-viral and monoclonal antibodies in top COVID-19 affected countries is also presented here. Considering the molecular interactions, therapeutic activity, efficacy, and adverse effects, the USFDA and the WHO recommended the aforementioned drugs. The chances of approval seems favouring biotherapeutics as these have the best characteristics among the chemotherapeutics. Overall, this review contributes to the scientific understanding of the COVID-19. This can help to inform future research and development efforts and contribute to the overall advancement of knowledge in the field of medicine. © 2022, HH Publisher. All rights reserved. HH Publisher 2022 Article PeerReviewed Vijay, Kotra and Mallem, Dinakar and Anil Kumar, Kanuri and Mahesh Reddy, Burra and Shaik, Nyamathullah and Ying, Looi Shu and Khairul Anwar, Husain and Vrala, Ravi and Sudhakar, Madhavedi and Goh, Khang Wen and Sam, Toong Hai and Long, Chiau Ming * (2022) Anti-SARS-CoV-2 Biotherapeutics and Chemotherapeutics: An Insight into Product Specifications and Marketing Dynamics. Progress in Microbes & Molecular Biology, 5 (1). ISSN 2637-1049 https://doi.org/10.36877/pmmb.a0000323 10.36877/pmmb.a0000323 |
institution |
Sunway University |
building |
Sunway Campus Library |
collection |
Institutional Repository |
continent |
Asia |
country |
Malaysia |
content_provider |
Sunway University |
content_source |
Sunway Institutional Repository |
url_provider |
http://eprints.sunway.edu.my/ |
topic |
RA Public aspects of medicine RM Therapeutics. Pharmacology |
spellingShingle |
RA Public aspects of medicine RM Therapeutics. Pharmacology Vijay, Kotra Mallem, Dinakar Anil Kumar, Kanuri Mahesh Reddy, Burra Shaik, Nyamathullah Ying, Looi Shu Khairul Anwar, Husain Vrala, Ravi Sudhakar, Madhavedi Goh, Khang Wen Sam, Toong Hai Long, Chiau Ming * Anti-SARS-CoV-2 Biotherapeutics and Chemotherapeutics: An Insight into Product Specifications and Marketing Dynamics |
description |
Chemotherapeutics and biotherapeutics agents have been explored as a potential treatment for COVID-19. This study was aimed to elucidate latest update related to biotherapeutics and chemotherapeutics against COVID-19 and its variants as well as the product specifications and marketing dynamics of its pharmacotherapies. There are several chemotherapeutics that have been studied for the treatment of COVID-19, including Paxlovid (Nirmatrelvir & Ritonavir) fixed dose combination, nirmatrelvir and ritonavir fixed dose combination, Remdesivir (Vekulary/Covifor) fixed dose combination, chloroquine and hydroxychloroquine, molnupiravir, favipiravir, Infliximab (Remsima®) fixed dose combination tocilizumab (Actimera), casirivimab+imdevimab (Ronapreve) fixed dose combination, ivermectin, methylprednisole. These drugs have been repurposed for use in COVID-19 due to their antiviral properties and ability to reduce inflammation. The COVID-19 death cases have significantly reduced because of tested efficacy of advanced biotherapeutics and chemotherapeutics. As for marketing dynamics, the demand for chemotherapeutics for the treatment of COVID-19 has increased significantly since the outbreak of the pandemic. Hence, the prices of anti-viral and monoclonal antibodies in top COVID-19 affected countries is also presented here. Considering the molecular interactions, therapeutic activity, efficacy, and adverse effects, the USFDA and the WHO recommended the aforementioned drugs. The chances of approval seems favouring biotherapeutics as these have the best characteristics among the chemotherapeutics. Overall, this review contributes to the scientific understanding of the COVID-19. This can help to inform future research and development efforts and contribute to the overall advancement of knowledge in the field of medicine. © 2022, HH Publisher. All rights reserved. |
format |
Article |
author |
Vijay, Kotra Mallem, Dinakar Anil Kumar, Kanuri Mahesh Reddy, Burra Shaik, Nyamathullah Ying, Looi Shu Khairul Anwar, Husain Vrala, Ravi Sudhakar, Madhavedi Goh, Khang Wen Sam, Toong Hai Long, Chiau Ming * |
author_facet |
Vijay, Kotra Mallem, Dinakar Anil Kumar, Kanuri Mahesh Reddy, Burra Shaik, Nyamathullah Ying, Looi Shu Khairul Anwar, Husain Vrala, Ravi Sudhakar, Madhavedi Goh, Khang Wen Sam, Toong Hai Long, Chiau Ming * |
author_sort |
Vijay, Kotra |
title |
Anti-SARS-CoV-2 Biotherapeutics and Chemotherapeutics: An Insight into Product Specifications and Marketing Dynamics |
title_short |
Anti-SARS-CoV-2 Biotherapeutics and Chemotherapeutics: An Insight into Product Specifications and Marketing Dynamics |
title_full |
Anti-SARS-CoV-2 Biotherapeutics and Chemotherapeutics: An Insight into Product Specifications and Marketing Dynamics |
title_fullStr |
Anti-SARS-CoV-2 Biotherapeutics and Chemotherapeutics: An Insight into Product Specifications and Marketing Dynamics |
title_full_unstemmed |
Anti-SARS-CoV-2 Biotherapeutics and Chemotherapeutics: An Insight into Product Specifications and Marketing Dynamics |
title_sort |
anti-sars-cov-2 biotherapeutics and chemotherapeutics: an insight into product specifications and marketing dynamics |
publisher |
HH Publisher |
publishDate |
2022 |
url |
http://eprints.sunway.edu.my/3013/ https://doi.org/10.36877/pmmb.a0000323 |
_version_ |
1806692472646008832 |
score |
13.18916 |